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ABSTRACT
Purpose: The 8th edition of the American Joint Committee on Cancer (AJCC) staging manual 
introduced a new prognostic staging system for breast cancer. This study aimed to evaluate 
the changes in staging distribution and predictive power of the new staging system.
Methods: Of the 12,275 patients with breast cancer identified from the Severance Breast 
Cancer Registry who underwent surgery between 1978 and 2016, 12,125 patients met the 
inclusion criteria.
Results: In both the 7th and 8th staging systems, stage I patients constituted the largest 
proportion (38.2% and 48.4%). Migration from the 7th to 8th edition of the AJCC manual 
resulted in a decrease in stage II population and an increase in stage I and III populations. 
A total of 1,293 (15.4%) patients were upstaged, and 1,201 (14.3%) were downstaged. 
Downstaged patients had better recurrence-free and overall survival (p < 0.001). Pathologic 
complete response after neoadjuvant therapy showed good prognosis as p stage 0, and yp 
stages I and III showed poorer outcomes than the same p stage (p < 0.001).
Conclusions: Staging migrations are common in early breast cancer under the prognostic 
staging system. The prognostic staging system of the 8th edition of the AJCC manual 
discriminates survival outcomes better than the anatomical staging system of the 7th edition 
of the AJCC manual.
Keywords: Breast neoplasms; Prognostic staging
INTRODUCTION
Cancer staging enables clinicians and researchers to uniformly describe the extent of disease 
and effectively communicate treatment plans and prognosis [1]. Modern cancer staging of 
breast cancer is primarily based on the American Joint Committee on Cancer (AJCC) staging 
system, which was recently revised in 2017 [2].
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The AJCC cancer staging manual standardized the TNM classification, which classifies tumors 
by size, lymph node metastasis, and distal metastasis [3]. The AJCC manual incorporates 
universal information and understanding of research and is made available to all countries. In 
addition, the AJCC cancer staging system is applicable to lower and middle-income countries 
because it requires only basic anatomic information. Hence, clinicians, tumor registrars, 
patients, and patient advocates use the AJCC staging system worldwide [2,4].
The previous (7th edition) AJCC manual staged cancers solely according to anatomic 
information. This approach did not consider the remarkable progress of modern molecular 
biology and the importance of biologic markers, including tumor markers, hormonal-receptor 
status, histologic findings, and gene expression when planning treatment and predicting 
cancer prognosis [5,6]. Therefore, a panel of AJCC experts revised the traditional guidelines 
to include biomarkers. This renewed staging system is the cornerstone of the next-generation 
AJCC staging system, which is meant to provide a more precise and personalized approach [4].
Major changes to breast cancer staging were incorporated into the 8th edition of the AJCC 
manual because of the heterogeneous features and diverse biomarkers in breast cancer that 
can influence treatment plans and prognosis [7]. First, lobular carcinoma in situ (LCIS) was 
reclassified as a benign lesion and removed from the list of malignant tumor entities. Second, 
the pathological classification of residual tumor following neoadjuvant chemotherapy 
(NCT) was clarified and strongly recommended. Third and most importantly, the revision 
established a completely new prognostic staging table that utilized biomarkers, including 
histologic grade, estrogen receptor (ER) expression, progesterone receptor (PR) expression, 
human epidermal growth factor receptor 2 (HER2) expression, and gene expressions [1,6,8].
Therefore, the aim of this study was to investigate the impacts of the revision on the existing 
stage distributions and assess the predictive power of the revised prognostic staging system.
METHODS
We accessed the Severance Breast Cancer Registry, which was described in a previous study 
[9], and identified 12,275 patients who underwent definitive surgery for the treatment of 
breast cancer at Severance Hospital from February 1978 to August 2016. We reviewed the 
following clinicopathologic data: tumor size; nodal metastasis; distant metastasis; histologic 
grade; ER, PR, and HER2 expressions; and the 21-gene Oncotype Dx® (Genomic Health, Inc., 
Redwood City, US). In addition, we reviewed the patients' demographic data, including age, 
patterns and date of recurrence, and date of death.
The ER and PR status of the patients was determined by an immunohistochemistry (IHC) 
assay or a ligand-binding assay. Tumors with ≥ 1% nuclear-stained cells were considered 
positive for ER and PR, and this interpretation is consistent with the American Society of 
Clinical Oncology/College of American Pathologists (ASCO/CAP) guidelines [10]. HER2 was 
scored by counting the number of membrane-stained cells, and the positively stained cells 
were reported as a percentage of the total tumor cells. This interpretation is also consistent 
with the ASCO/CAP guidelines [9]. Furthermore, HER2 was considered positive if gene 
amplification was detected by fluorescence in situ hybridization (FISH), regardless of the 
HER2 IHC results [11]. Previous studies have provided a description of the IHC and FISH 
testing used in this study [9,11].
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We excluded 150 patients who had incomplete anatomic information. Hence, data from 
12,125 patients were analyzed according to the 7th edition of the AJCC manual. We further 
excluded 3,706 patients who had incomplete prognostic information such as missing 
hormonal receptor status or histologic grade data. Finally, data from 8,419 patients were 
analyzed according to the 8th edition of the AJCC manual (Figure 1). When patients were 
staged with their genomic data (n = 139), we considered the Oncotype Dx® multi-gene assay 
score. The 8th edition of the AJCC manual had missing subgroups of TNM stages at first [2]. 
For the missing subgroups, we applied the AJCC software, TNM Cancer Staging Calculator, 
version 16 (Integrated Cancer Research Ltd., London, UK) to categorize them by the 
prognostic staging system.
Statistical analysis
The intergroup differences were evaluated using the t-test for continuous variables and the 
χ2 test for categorical variables. We defined overall survival (OS) as the period from the day of 
operation to the date of death from all causes or date of last visit to the hospital. Recurrence-
free survival (RFS) was measured from the day of operation to the date of the first recurrence 
event, death from any cause, and/-or the last follow up. Survival curves were plotted using the 
Kaplan-Meier method, and intergroup differences in survival time were investigated using 
the log-rank test. All statistical tests were 2-sided, and a p-value of < 0.05 was considered 
statistically significant. SPSS for Windows version 23.0 (IBM Corp., Armonk, USA) was used 
for all statistical analyses.
The independent Institutional Review Board of Severance Hospital approved this study 
(approval number: 4-2019-0174), and the need for written informed consents was waived 
because of the low risk posed by this research.
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Patients underwent mastectomy for primary invasive 
breast cancer from Feb 2, 1978 to Aug 31, 2016
(n=12,275)
Exclusion
Incomplete anatomic information (n=150)
Exclusion






Exclusion d/t lack of HER2
Exclusion d/t lack of ER
Exclusion d/t lack of PR




Figure 1. Flow diagram of study cohort. 
AJCC = American Joint Committee on Cancer; HER2 = human epidermal growth factor receptor 2; ER = estrogen 
receptor; PR = progesterone receptor.
RESULTS
Patient demographics
The patients' clinicopathologic characteristics are shown in Table 1. Females accounted for 99.3% 
of the study population, and the median age was 49.0 years (range, 17–93 years). The proportion 
of patients aged ≤ 50 years was higher than those aged > 50 years. Half of the patients (51.2%) 
were classified as T1, followed by T2 (28.2%) and Tis (14.4%). In total, 65 patients had only LCIS 
constituting 3.0% in situ carcinoma according to the 7th edition of the AJCC manual. Further, 70% 
patients had no regional lymph node metastasis (N0), and the proportion of patients decreased 
in each successive N stage. Grade 2 histologic tumors were found in 36.4% patients. Similar 
proportions of patients had grades 1 and 3 tumors (17.4%). More than 60% of the study group was 
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Table 1. Characteristics of the study population (n=12,125)
Characteristics No. (%)
Age (yr)
≤ 50 6,826 (56.3)









































ER = estrogen receptor; PR = progesterone receptor; HER2 = human epidermal growth factor receptor 2; NCT = 
neoadjuvant chemotherapy.
ER positive, and half of the tumors were PR positive. HER2-negative tumors were more common 
than HER2-positive tumors (52.0% vs. 17.1%), and one-third patients had unknown HER2 status 
(30.9%). Thirteen percent of patients received preoperative chemotherapy.
Stage distribution and migration
The 7th and 8th editions of the AJCC manual had identical anatomic staging guidelines, 
except for in situ carcinoma. The study patients’ anatomic staging was distributed as follows: 
1,975 (16.3%) were stage 0, 4,598 (37.9%) were stage I, 3,999 (33.0%) were stage II, 1,448 
(11.9%) were stage III, and 105 (0.9%) were stage IV. The study patients' prognostic staging 
was distributed as follows: 1,910 (15.8%) were stage 0, 3,650 (30.1%) were stage I, 1,450 
(12.0%) were stage II, 1,239 (10.2%) were stage III, and 105 (0.9%) were stage IV. Figure 2  
shows the differences in stage distribution between the two staging systems. The most 
noticeable changes were the decrease in the stage II population and the increase in the stage I 
and III populations.
Figure 2 shows the migration of populations in each stage group. The most frequent 
movement was from anatomic stage II to prognostic stage I (n = 996), followed by anatomic 
stage II to prognostic stage III (n = 695), anatomic stage I to prognostic stage II (n = 597), 
and anatomic stage III to prognostic stage II (n = 173). Thirty-two patients were stage III 
according to anatomic staging, but the staging was changed to stage I according to the 
prognostic staging.
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AJCC 8th prognostic staging
Total




Stage 0 1,910 0 0 0 0 65 1,975
Stage I 0 2,622 597 1 0 0 3,220
Stage II 0 996 680 695 0 0 2,371
Stage III 0 32 173 543 0 0 748
Stage IV 0 0 0 0 105 0 105
Total 1,910 3,650 1,450 1,239 105 65 8,419
Stage 0 Stage I
AJCC 8th Prognostic staging frequency



















Figure 2. Stage migration of study population. 
AJCC = American Joint Committee on Cancer; LCIS = lobular carcinoma in situ as a benign entity.
Survival analysis according to the staging systems of the 7th and 8th editions 
of the AJCC manual
The OS and RFS of each stage group were discriminated by the anatomic and prognostic 
staging systems (p < 0.001). According to the anatomic staging system, the 5- and 10-
year OS for each stage is as follows: 97.2% and 93.6% for stage 0, 96.5% and 0, 90.1% for 
stage I, 91.0% and 81.5% for stage II, 72.5% and 56.7% for stage III, and 40.3% and 12.6% 
for stage IV, respectively. According to the prognostic staging system, the 5- and 10-year 
OS for each stage is as follows: 97.3% and 93.6% for stage 0, 97.1% and 90.7% for stage 
I, 93.0% and 83.4% for stage II, 77.5% and 67.0% for stage III, and 40.3% and 12.6% for 
stage IV, respectively (Supplementary Table 1). The RFS for each staging system is shown in 
Supplementary Table 2.
The movement of patients from the anatomic staging system to the prognostic staging 
system resulted in the upstaging of 1,293 patients and the downstaging of 1,201 patients. 
The changes in OS and RFS according to upstaging or downstaging are represented in 
Figure 3. The patients downstaged from stage II to stage I in the prognostic staging system 
experienced better outcomes, and those upstaged from stage II to stage III in the prognostic 
staging system had worse outcomes than those who remained in the same stage (p < 0.001). 
This trend was also observed in stages I and III. There was no significant difference in RFS 
between the patients downstaged from III to II and those from III to I (p = 0.635).
Survival analysis according to NCT
A total of 1,569 patients received NCT. For the patients staged I or III after NCT and 
subsequent surgery, their prognosis was poorer than those at the same stage without NCT (p 
< 0.001). The patients at stage 0 after NCT and surgery tended to have worse outcomes than 
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p = 0.001










Stage I (An) to III (Pr)
Stage I (An) to II (Pr)
Stage unchanged
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Stage II (An) to III (Pr)
Stage II (An) to I (Pr)
Stage unchanged
p < 0.001










Stage III (An) to II (Pr)
Stage III (An) to I (Pr)
Stage unchanged
p = 0.060
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Stage unchanged
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Stage II (An) to III (Pr)
Stage II (An) to I (Pr)
Stage unchanged
p < 0.001










Stage III (An) to II (Pr)
Stage III (An) to I (Pr)
Stage unchanged
Figure 3. Changes of RFS (A-C) and OS (D-F) according to migration of anatomic stage (A and D) I, (B and E) II, (C and F) III. 
An = anatomic stage according to AJCC 7th edition; Pr = prognostic stage according to AJCC 8th edition; AJCC = American Joint Committee on Cancer; RFS = 
recurrence-free survival; OS = overall survival.
those without NCT, but the trend was not statistically significant (p = 0.065). The prognosis 
of p- and yp-stages showed no difference for stage II.
DISCUSSION
Our study demonstrates that the prognostic staging system of the 8th edition of the AJCC 
manual increases the proportion of stages I and III and decreases the proportion of stage II when 
compared to the anatomical staging system of the 7th edition of the AJCC manual. Our results are 
consistent with those of previous studies [12,13]. In this study, the change of stage distribution 
was primarily due to the migration from stage II. The largest migration was from stage II to stage 
I, which was approaching the sum of the migrations to stage II from stage III and I. Hence, the 
distribution of the study population became more bipolarized under the prognostic staging 
system. This suggests that the new guideline distributes the patients more towards good or poor 
prognosis groups (stage I or III) rather than the equivocal prognosis group (stage II).
The prognostic staging system discriminated survival better than the anatomical staging 
system. Downstaged patients showed better survival than the unchanged or upstaged patients 
(Figure 3), a finding consistent with those of previous studies [1,7,12,14]. Thus, the prognostic 
staging system of the 8th edition of the AJCC manual shows better discrimination of survival 
outcomes than the anatomical staging system of the 7th edition of the AJCC manual.
This study showed differences in survival outcomes between the patients with 
recommendations for neoadjuvant pathologic tumor-node-metastasis staging (ypTNM) 
and those with pathological tumor-node-metastasis staging (pTNM) even though they had 
the same stages. The patients with stages I and III after NCT (yp stage I and III) showed 
significantly poorer survival than those with the same stage without NCT. Because the stages 
after NCT were all residual cases, the worse outcomes may be related to chemoresistance. In 
general, patients with residual chemo-resistant tumors have poorer survival than those with 
pathologic complete response after neoadjuvant therapy (ypCR) [15-18].
The survival outcomes of patients with stages 0 and II breast cancer after NCT were not 
significantly different (Figure 4). Because we combined ypT0N0M0 and ypTisN0M0 
after NCT into yp stage 0, they were all considered ypCR. ypCR showed excellent survival 
outcomes in previous studies [16,17,19]. Moreover, a previous study reported that patients 
with ypCR experienced the best survival outcomes, and the recurrence rate and mortality 
increased significantly as the ypTNM stage increased [16]. The study results suggested that 
the survival outcomes of ypCR were not significantly different in the patients with in situ 
carcinoma without NCT [19]. Therefore, when patients have achieved complete pathologic 
remission after NCT, their outcomes may be similar to those with primary stage 0 breast 
cancer. No differences in survival outcomes were observed between yp and p stage II. Further 
investigations are warranted to evaluate the implication of stage II after NCT.
The current study had some limitations. In particular, approximately 30% patients had an 
unknown HER2 status in the registry because of a lack of HER2 overexpression assays prior 
to 2010. Hence, application of HER2 status to the prognostic staging system was limited. In 
addition, selection bias may exist due to the retrospective single-center nature of this study. 
However, the patient populations in this study received equivalent surgical procedures and 
pre- and postoperative treatment, which made the study populations homogeneous. When 
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the 8th edition of the AJCC manual was published, the prognostic staging table had missing 
subgroups [1], and there were > 20 uncategorized combinations of T, N, grade, and hormonal 
receptor statuses. We integrated those patient groups into the prognostic staging system 
using a recent software to assist with the AJCC cancer staging.
This study demonstrates that the prognostic staging system of the 8th edition of the AJCC 
manual discriminates survival outcomes better than the anatomical staging system of the 7th 
edition of the AJCC manual. Staging migration from stage II in the anatomical staging system 
to stage I or III in the prognostic staging system was commonly observed. ypCR showed 
excellent survival outcomes and no statistically significant difference in survivals compared 
to in situ carcinomas. The new staging system appears to be a superior alternative to the 
conventional anatomic staging system.
SUPPLEMENTARY MATERIALS
Supplementary Table 1
OS of each staging system
Click here to view
Supplementary Table 2
RFS of each staging system
Click here to view
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p = 0.094
































































Figure 4. Changes of OS according to NCT in each prognostic stage; (A) stage 0, (B) stage I, (C) stage II, (D) stage III, (E) stage IV. 
OS = overall survlval; NCT = neoadjuvant chemotherapy.
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